MA
Therapeutic Areas
Organon Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AYA™ (etonogestrel) contraceptive vaginal system | Contraception | Filed |
| MK-8189 (deudomperidone) | Vasomotor symptoms due to menopause | Phase 3 |
| Biosimilar to Stelara® (ustekinumab) | Immunology (e.g., plaque psoriasis, Crohn's disease) | Phase 3 |
| Biosimilar to Eylea® (aflibercept) | Ophthalmology (neovascular AMD) | Phase 3 |
| Biosimilar to Prolia®/Xgeva® (denosumab) | Bone health / Oncology | Phase 3 |
| Biosimilar to Simponi® (golimumab) | Immunology (e.g., rheumatoid arthritis) | Phase 3 |
Leadership Team at Organon
KA
Kevin Ali
Director & Chief Executive Officer
SF
Susanne Fiedler
Chief Financial Officer
SM
Sandra Milligan, M.D., J.D.
Head of Research & Development
DJ
Dr. Juan Camilo Arjona Ferreira
Chief Medical Officer
JH
Jennifer Halchak
Head of Strategy and Business Development